FindTrial
Sign In

Effect of levetiracetam and sodium valproate mono therapy on serum vitamin D and serum calcium levels in Pediatric epileptic patients in tertiary care hospital, Haldwani, Uttarakhand

EFFECT OF LEVETIRACETAM AND SODIUM VALPROATE MONOTHERAPY ON SERUM 25-HYDROXY VITAMIN D, SERUM CALCIUM , SERUM PHOSPHATE AND SERUM ALKALINE PHOSPHATE LEVELS IN PEDIATRIC EPILEPTIC PATIENTS IN TERTIARY CARE HOSPITAL,HALDWANI, UTTRAKHAND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/049325
Enrollment
148
Registered
2023-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Control Intervention1: Levetiracetam and sodium valproate: Patient will be initiated initially levetiracetam @40mg/kg and will be titrating to max of @60mg/kg/day and valproate initially at @20mg/kg t

Sponsors

Dr Yashi Gupta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All newly diagnosed patients (age- 1 to 16 years) of epilepsy coming to pediatrics OPD and pediatric ward who will be initiated on sodium valproate or levetiracetam monotherapy 2. Patientâ??s parents who have given written informed consent. Assent from children more than 9 years of age if feasible (conscious and oriented child with normal intelligence).

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA 1. Children with episode of febrile convulsion 2.Epileptic children who are seizure free and had stopped taking medication for 3 or more years 3.Children on vitamin D supplementation 4.Children with metabolic bone disease. 5.Children with significant renal, hepatic, endocrine disorders which will effect vitamin D and calcium metabolism. 6. Patients with epilepsy who are on antiepileptic polytherapy. 7.Patients who are in need of critical care and are bed ridden

Design outcomes

Primary

MeasureTime frame
1.To observe the effect of levetiracetam monotherapy on serum 25-hydroxy vitamin D levels, serum calcium, serum phosphate and serum alkaline phosphatase. 2.To observe the effect of sodium valproate monotherapy on serum 25- hydroxy vitamin D levels, serum calcium, serum phosphate and serum alkaline phosphatase. 3. To observe and analyze the effects of levetiracetam and sodium valproate monotherapies on serum 25- hydroxy vitamin D levels, serum calcium, serum alkaline phosphatase.Timepoint: 6 months—

Secondary

MeasureTime frame
To study the clinico-socio demographic profile of patients with epilepsyTimepoint: During study period of 18 months—

Countries

India

Contacts

Public ContactDr Yashi Gupta

Government medical college Haldwani

lalitriturakholia@rediffmail.com9410502874

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026